Lisata Therapeutics Inc (LSTA)

Buyout is for $4, plus two $1 CVRs. One CVR is for the transfer of certepetide rights in China back to LSTA. The other is for when Kuva files an NDA.

The first CVR is going to be paid out, we already know that LSTA regained the rights in China. You're basically guaranteed $5 at this point, with a shot at getting $6 if the 2nd CVR gets paid.

LSTA..............................................https://stockcharts.com/sc3/ui/?s=LSTA&p=W&b=5&g=0&id=p86431144783

Sounds like more data is coming soon? Is OS still under 9/10 million?

LSTA news .. Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent https://investorshub.advfn.com/stock-market/NASDAQ/lisata-therapeutics-LSTA/stock-news/97152057/lisata-therapeutics-highlights-positive-preclinica

"Under the terms of the agreement, Lisata is eligible to receive over $10 million in tiered study initiation milestone payments plus revenue sharing on future sales and partnerships.

"Catalent gains global rights to evaluate certepetide for ADC payloads"
https://in.investing.com/news/company-news/catalent-gains-global-rights-to-evaluate-certepetide-for-adc-payloads-93CH-5035340

This one will run eventually

https://www.stocktitan.net/news/LSTA/lisata-therapeutics-and-warpnine-announce-i-lsta-trial-enrollment-7nhvc7oo1k1a.html

"Lisata Therapeutics stock price target raised to $32 from $20 at Brookline"
https://ca.investing.com/news/analyst-ratings/lisata-therapeutics-stock-price-target-raised-to-32-from-20-at-brookline-93CH-4102825

Lsta is getting a lot of volume with the prhttps://www.proactiveinvestors.com/companies/news/1074770/lisata-therapeutics-expands-ip-with-key-patent-covering-certepetide-s-chemical-structure-and-uses-1074770.html?region=ca

https://www.stocktitan.net/news/LSTA/lisata-therapeutics-expands-intellectual-property-portfolio-with-new-qelrl0cqu18a.html

She's going to fly....glta 

The bids are stacking...breakout imminent....glta 

Is anyone still in this? 

https://kalkinemedia.com/news/world-news/constrained-peptide-drugs-global-market-projected-to-reach-613-billion-by-2029

news out https://www.globenewswire.com/news-release/2025/06/26/3105796/18623/en/Positive-Preliminary-Cohort-B-Results-from-the-AGITG-led-ASCEND-Trial-to-be-Presented-at-ESMO-GI-Evaluating-Lisata-s-Certepetide-in-Combination-with-Standard-of-Care-Chemotherapy-i.html

https://www.proactiveinvestors.com/companies/news/1073130/lisata-therapeutics-to-lead-development-of-oud-therapy-under-expanded-alliance-with-gatc-health-1073130.html?region=ca

$2.10 -BOUNCER- Preliminary results from Cohort B data have been accepted for presentation at the ESMO Gastrointestinal Cancers Congress being held July 2-5, 2025.

ASCEND: Phase 2b double-blind, randomized (2:1 ratio), placebo-controlled trial evaluating two dosing regimens of certepetide in combination with SoC chemotherapy (gemcitabine/nab-paclitaxel) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial is being conducted across 25 sites in Australia and New Zealand led by the Australasian Gastro-Intestinal Trials Group (AGITG) and coordinated by the National Health and Medical Research Council Clinical Trial Centre at the University of Sydney. Cohort A, with 95 patients receiving a single intravenous (IV) dose of certepetide 3.2 mg/kg or placebo in combination with SoC, completed enrollment in the third quarter of 2023. Preliminary Cohort A data presented at the 2025 ASCO-GI Symposium showed a positive trend in overall survival, including four complete responses in the certepetide-treated group compared to none in the placebo treated group. Data from Cohort B, with 63 patients receiving two IV doses of certepetide 3.2 mg/kg or placebo administered 4 hours apart in combination with SoC, is expected in the coming months with a final analysis of both cohorts available thereafter.

https://www.biospace.com/press-releases/lisata-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update

LSTA recent 52 week low

"Lisata, Catalent partner for cancer drug research"
https://au.investing.com/news/company-news/lisata-catalent-partner-for-cancer-drug-research-93CH-3785178

Looks tempting here

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169956690

Never mind I see they did change the ticker and wow great job. CUDOS to you!

The ticker it is LSTA get on etrade market castor that is what I am on

Did they change the ticker?tia

It going through the roof right now I left 5000 on the table who knew it was going over 9.00 wow volume at over 627000 now premarket

CONGRAT$

It shows 615000 premarket on etrade market castor and it over 9.00 a share now wow

But the stock shows 0 trades pre mkt???

Clbs my second best play this week wow!! When everyone was saying it was tanking big time sold this morning for a nice Gain

Wow I got up this morning and it was over 7.50 I called etrade and they put my sell order through I just made 2400.00 profit when everyone even moonmarket said it was a bad trade for him ,I bought at .40 yesterday 7.50is like selling it for .60 at the old share structure

You're absolutely correct. I will keep this on watch.

lately everything is a pnd, they push it up too high and short it back

with some exceptions, that have a few day run

I have been reading all about it on OTC site and stock twits I put a bid in for .385 just for the fun of it

Merger news this morning mixed with the r/s is why I bought. Took loss and keeping it on radar for reversal

YOU BOUGHT AT .63 IT WAS JUST AT .385

Yea, nothing surprises me

Looks like a group wacked out to chase another ticker

Watching for bounce from 52 WL

I didn't get the memo. lol

Maybe someone didn't get the memo that r/s plays are hot right now haha

Snagged 63s

LMAO!

LOLme2

This is a very unusual year with all the R/S working out! Scratching my bald head!

post RS plays are HOT **CLBS* +Merger

adtx nrbo

Yep double whammy r/s and merger. Surprised this isn't getting more attention

Merger in progress

R/s after the close. Could be another big runner

Dawson James - Caladrius (CLBS) - Delays, Delays & delays + Burning Cash

Caladrius has fallen to $0.90 from $1.61 (2.15.21) when we wrote "Dam the Shareholders Full Speed Ahead", commenting on the highly dilutive capital raise. Revisiting the story, we see little progress. Caladrius reported 3Q21 results spending $7M in the quarter, steadily whittling down its $100M in cash balance but to what end? We note multiple delays across previously promoted programs such as CLI in Japan, now suspended.
Click here for the full report


HONDERA (CLBS12) – Suspended for CLI in Japan –This was planned as a small Phase 2 study, an interventional, open-label, proof-of-concept (POC) trial planned for two centers, but the company had problems finding patients, blaming COVID. Caladrius now says the program is suspended until a Japanese partner is identified. We remain skeptical and see this program as "dead."

XOWNA (CLBS16) – Enrollment has Slowed: The product is currently being evaluated in a P2b study in patients with CMD and without obstructive coronary artery disease. Patient enrollment is behind schedule, so the company has been expanding the number of sites and modifying the study protocol. These protocol amendments were implemented in the latter part of the quarter. We see these as "red flags."

Management was Pushing the CD34+ cells as a COVID Play – This appears to have fizzled out. Is anyone surprised? What's the Problem? On just about every level, we find management's explanations across multiple programs as lacking. Management seems to lack an understanding of 1. the competitive environment. Multiple off-the-shelf, allogeneic companies are already treating COVID patients but on ventilators and potentially earlier, and recent failures of other cell therapies in COVID due to improved standard of care. 2. For example, in COVID, using cells to ameliorate the after-effects of ventilator therapy for COVID patients is a great idea, BUT a) harvesting cells from these patients is not ideal; b) how do you measure how effective your treatment is? For NORDA, we see a POC trial as a $65M and multi-year investment. What size trial is needed to measure the effect versus standard of care? 3. Caladrius's autologous therapy is very late in the field.

Valuation. For Caladrius, we previously lowered our rating to Neutral from Buy (March 2020) and removed our price target. Our model uses our highest discount rate of 30% in our free cash flow to the Firm (FCFF), discounted EPS, and Sum of the Parts (SOP) models. Our models go out to 2029 and have been updated for the recent dilution. The company now has a negative enterprise value, but we believe that won't last as its likely management will now be on a spending spree. Spending on clinical trials that we feel go nowhere and or looking to make an acquisition. Our bottom-line concern is that Caladrius has, in our opinion, missed the window. Allogenic competitors are advancing now in heart failure, back pain, stroke, CLI, GvHD, and three companies are today treating COVID patients for ARDS

Risks to our thesis include the following: (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property.

Got new bagholders pos imo